Size	Price	VIP Price	US Stock	Global Stock	In Stock
{[ item.pr_size ]}		Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

CAS No. :	957054-30-7
Formula :	C₂₃H₂₇N₇O₃S₂
M.W :	513.64
SMILES Code :	CS(=O)(=O)N1CCN(CC2=CC3=C(S2)C(=NC(=N3)C2=C3C=NNC3=CC=C2)N2CCOCC2)CC1
Synonyms :	GDC-0941; GNE-0941; Pictrelisib
MDL No. :	MFCD11616196
InChI Key :	LHNIIDJUOCFXAP-UHFFFAOYSA-N
Pubchem ID :	17755052

GHS Pictogram:
Signal Word:	Warning
Hazard Statements:	H302-H315-H319-H332-H335
Precautionary Statements:	P280-P305+P351+P338-P310

MEB-Med-8A cells	1 μM	24 h	Pictilisib significantly inhibited the migration of MEB-Med-8A cells and altered the cytoskeleton structure.	PMC9716228
Daoy cells	1 μM	24 h	Pictilisib reduced the migration of Daoy cells, significantly decreased wound closure, and altered the cytoskeleton structure.	PMC9716228
KPwmC cells	1μM	30 min	To observe the effect of Pictilisib on p-CREB1S133 levels, results showed that Pictilisib reduced p-CREB1S133 levels.	PMC8338884
P14 CD8+ T cells	1 μM	3 to 4 days	Inhibition of PI3K activity, leading to defective CD3 polarity and Glut1 surface trafficking, reduced glucose uptake	PMC5806629
SW48-HER2	0.05 to 10 μM	96 h	To evaluate the anti-proliferative effects of Pictilisib on SW48-HER2 cells. Results showed that Pictilisib as a single agent exhibited dose-dependent cell growth inhibition in HER2-amplified cells.	PMC6549349
LIM1215-HER2	0.05 to 10 μM	96 h	To evaluate the anti-proliferative effects of Pictilisib on LIM1215-HER2 cells. Results showed that Pictilisib as a single agent exhibited dose-dependent cell growth inhibition in HER2-amplified cells.	PMC6549349
SW48-HER2 cells	0.05 to 10 μM	96 h	To evaluate the inhibitory effect of Pictilisib on cell proliferation, the results showed that Pictilisib monotherapy exhibited dose-dependent growth inhibition in HER2-amplified cells.	PMC6549349
LIM1215-HER2 cells	0.05 to 10 μM	96 h	To evaluate the inhibitory effect of Pictilisib on cell proliferation, the results showed that Pictilisib monotherapy exhibited dose-dependent growth inhibition in HER2-amplified cells.	PMC6549349
MIMCD3 cells	1 µM	10 h	Pictilisib significantly reduced phosphorylation of Akt, MAPKAP1, and GFAP, and increased the formation of Dendra2 CMA reporter puncta, indicating an increase in CMA activity.	PMC7557678
AML12 cells	2 µM	10 h	Pictilisib significantly reduced phosphorylation of Akt, MAPKAP1, and GFAP, and increased the formation of Dendra2 CMA reporter puncta, indicating an increase in CMA activity.	PMC7557678
NIH3T3 cells	500 nM	10 h	Pictilisib significantly reduced phosphorylation of Akt, MAPKAP1, and GFAP, and increased the accumulation of Dendra2 CMA reporter puncta, indicating an increase in CMA activity.	PMC7557678
Human NK cells	1 μM	2 hours	To evaluate the effect of MLN1117 on human NK cell-mediated cytotoxicity. Results showed that selective inhibition of p110α had minimal impact on human NK cell-mediated cytotoxicity.	PMC4051752

Nude mice	LIM1215-HER2 and SW48-HER2 tumor xenograft models	Oral	75 mg/kg	Once daily for 4 weeks	To evaluate the antitumor activity of Pictilisib in LIM1215-HER2 and SW48-HER2 tumor xenograft models. Results showed that Pictilisib as a single agent had little effect on tumor growth, but the combination with Refametinib almost completely suppressed tumor growth.	PMC6549349
Nude mice	LIM1215-HER2 and SW48-HER2 tumor xenografts	Oral	75 mg/kg	Every day, for 4 weeks	To evaluate the inhibitory effect of Pictilisib monotherapy and its combination with Refametinib on tumor growth, the results showed that the combination therapy significantly suppressed tumor growth and lasted up to 20 weeks after the end of treatment.	PMC6549349
Mice	Normal 3-month-old mice	Oral	100 mg/kg	Once per day for 7 days	Pictilisib significantly increased CMA substrate uptake in liver lysosomes and reduced lysosomal GFAP phosphorylation in mice, indicating an increase in CMA activity.	PMC7557678
Mice	MR86 patient-derived xenograft (PDX) model	Oral	150 mg/kg	Once daily for up to 40 days	To evaluate the inhibitory effect of Pictilisib in combination with Erdafitinib on tumor growth, the results showed that the combination treatment significantly inhibited tumor growth	PMC10481128

{[proInfo.proName]}

CAS No.: 957054-30-7

{[proInfo.proName]}

CAS No.: 957054-30-7

Alternative Products

Product Details of Pictilisib

Safety of Pictilisib

Related Pathways of Pictilisib

Isoform Comparison

Biological Activity

Protocol

References

Historical Records

Categories

Precautionary Statements-General

Prevention

Response

Storage

Disposal

Physical hazards

Health hazards

Environmental hazards

Inquiry

Molarity Calculator

Total Compounds Calculator

Dissolution Calculator

NCT02430363	Glioblastoma	Phase 1 Phase 2	Unknown	June 2018	United States, Massachusetts ... More >> Dana-Farber Cancer Institute Boston, Massachusetts, United States, 02115 United States, Texas M D Anderson Cancer Center Houston, Texas, United States, 77030 Belgium UCL- Cliniques Universitaires Saint Luc Brussels, Belgium Germany St Johannes Hospital Duisburg, Germany, 47166 Italy Spedali Civili di Brescia Brescia, Italy IRCCS San Raffaele Milan, Italy Poland Lower-Silesian Oncology Centre Wroclaw, Lower-Silesian, Poland, 53413 Russian Federation Pavlov State Medical University St. Petersburg, Russian Federation, 197089 Spain Hospital Universitario Germans Trias I Pujol Barcelona,, Spain Switzerland Universitätsklinik für Frauenheilkunde Bern, Switzerland Ukraine Regional Cancer Center Dnepropetrovsk, Ukraine, 49000 National Institute of Cancer Kiev, Ukraine, 03035 United Kingdom Royal Victoria Hospital Belfast, Ulster, United Kingdom, BT12 6BA Less <<
NCT02389842	Advanced Solid Tumours ... More >> Breast Cancer Less <<	Phase 1	Unknown	August 2017	United Kingdom ... More >> The Royal Marsden NHS Foundation Trust Recruiting London, United Kingdom, SM2 5PT Contact: Timothy Yap, PhD 02086613539 timothy.yap@icr.ac.uk Principal Investigator: Timothy Yap, PhD The Christie NHS Foundation Trust Not yet recruiting Manchester, United Kingdom, M20 4BX Contact: Anne Amstrong, MBBS 0161 446 3746 elaine.mercer@christie.nhs.uk Principal Investigator: Anne Armstrong, MBBS Less <<
NCT02092831	Healthy Volunteer	Phase 1	Completed	-	United States, Wisconsin ... More >> Madison, Wisconsin, United States, 53704 Less <<
NCT00960960	Breast Cancer	Phase 1	Completed	-	United States, Illinois ... More >> Peoria, Illinois, United States, 61615 United States, Massachusetts Boston, Massachusetts, United States, 02115 United States, Tennessee Nashville, Tennessee, United States, 37232 Belgium Leuven, Belgium, 3000 Italy Milano, Lombardia, Italy, 20133 Less <<
NCT00974584	Non-Squamous Non-Small Cell Lu... More >>ng Cancer Less <<	Phase 1	Completed	-	United States, New York ... More >> Buffalo, New York, United States, 14263 France Villejuif, France, 94805 Netherlands Groningen, Netherlands, 9700 RB Less <<
NCT01493843	Non-Small Cell Lung Cancer	Phase 2	Completed	-	-
NCT00999128	Healthy Volunteers	Phase 1	Completed	-	United States, California ... More >> Genentech Trial Information Support South San Francisco, California, United States, 94080 Less <<
NCT01437566	Breast Cancer	Phase 2	Completed	-	-
NCT00996892	Solid Tumors	Phase 1	Terminated(A recommended Phase... More >> 2 dose and schedule was not identified and the study was terminated before initiation of Stage 2B.) Less <<	-	United States, Maryland ... More >> Baltimore, Maryland, United States, 21231 United States, Massachusetts Boston, Massachusetts, United States, 02114 Boston, Massachusetts, United States, 02215 United States, Michigan Detroit, Michigan, United States, 48201 United States, Oklahoma Oklahoma City, Oklahoma, United States, 73104 United States, Tennessee Nashville, Tennessee, United States, 37203 Less <<
NCT00928330	Metastatic Breast Cancer	Phase 1	Completed	-	United States, Indiana ... More >> Indianapolis, Indiana, United States, 46202 United States, Maryland Baltimore, Maryland, United States, 21231 United States, Massachusetts Boston, Massachusetts, United States, 02115 Less <<
NCT01240226	Healthy Volunteer	Phase 1	Completed	-	United States, Texas ... More >> Investigational Site Austin, Texas, United States, 78744 Less <<
NCT00975182	Non-Squamous Non-Small Cell Lu... More >>ng Cancer, Solid Cancers Less <<	Phase 1	Completed	-	United States, Colorado ... More >> Aurora, Colorado, United States, 80045 United States, New Jersey New Brunswick, New Jersey, United States, 08903 Netherlands Amsterdam, Netherlands, 1066 EC Utrecht, Netherlands, 3508 GA Less <<
NCT01474668	Healthy Volunteer	PHASE1	COMPLETED	2025-10-11	Madison, Wisconsin, 53704-2523... More >>, United States Less <<
NCT00996892	-		Terminated(A recommended Phase... More >> 2 dose and schedule was not identified and the study was terminated before initiation of Stage 2B.) Less <<	-	-
NCT00876122	Non-Hodgkin's Lymphoma, Solid ... More >>Cancers Less <<	PHASE1	COMPLETED	2025-07-12	Sutton, SM2 5PT, United Kingdo... More >>m Less <<
NCT01918306	Estrogen Receptor Negative Bre... More >>ast Cancer Human Epidermal Growth Factor 2 Negative Carcinoma of Breast Triple Negative Breast Cancer Recurrent Breast Cancer Stage IV Breast Cancer Triple-negative Breast Cancer Less <<	Phase 1 Phase 2	Terminated(company stopped pro... More >>duction of study drug due to excessive toxicities, lack of efficacy) Less <<	-	United States, Alabama ... More >> University of Alabama Birmingham, Alabama, United States United States, California University of California, San Francisco San Francisco, California, United States United States, District of Columbia Georgetown University Washington, D.C., District of Columbia, United States United States, Georgia Emory University Atlanta, Georgia, United States United States, Illinois University of Chicago Chicago, Illinois, United States United States, Indiana Indiana University Indianapolis, Indiana, United States United States, Maryland John Hopkins University Baltimore, Maryland, United States United States, Massachusetts Dana Farber Cancer Institute Boston, Massachusetts, United States United States, Michigan University of Michigan Ann Arbor, Michigan, United States United States, Minnesota Mayo Clinic Rochester, Minnesota, United States United States, New York Memorial Sloan-Kettering Cancer Center New York, New York, United States United States, North Carolina University of North Carolina Charlotte, North Carolina, United States United States, Pennsylvania University of Pittsburgh Pittsburgh, Pennsylvania, United States United States, Tennessee Vanderbilt-Ingram Cancer Center Nashville, Tennessee, United States, 37232 United States, Texas Baylor Breast Center Houston, Texas, United States United States, Washington University of Washington Seattle, Washington, United States Less <<
NCT01740336	Breast Cancer	Phase 2	Completed	-	-
NCT01918306	-		Terminated(company stopped pro... More >>duction of study drug due to excessive toxicities, lack of efficacy) Less <<	-	-
NCT00876109	Solid Cancers	PHASE1	COMPLETED	2025-11-13	Scottsdale, Arizona, 85258, Un... More >>ited States\|Boston, Massachusetts, 02215, United States\|Detroit, Michigan, 48201, United States Less <<

Precautionary Statements-General
Code	Phrase
P101	If medical advice is needed,have product container or label at hand.
P102	Keep out of reach of children.
P103	Read label before use
Prevention
Code	Phrase
P201	Obtain special instructions before use.
P202	Do not handle until all safety precautions have been read and understood.
P210	Keep away from heat/sparks/open flames/hot surfaces. - No smoking.
P211	Do not spray on an open flame or other ignition source.
P220	Keep/Store away from clothing/combustible materials.
P221	Take any precaution to avoid mixing with combustibles
P222	Do not allow contact with air.
P223	Keep away from any possible contact with water, because of violent reaction and possible flash fire.
P230	Keep wetted
P231	Handle under inert gas.
P232	Protect from moisture.
P233	Keep container tightly closed.
P234	Keep only in original container.
P235	Keep cool
P240	Ground/bond container and receiving equipment.
P241	Use explosion-proof electrical/ventilating/lighting/equipment.
P242	Use only non-sparking tools.
P243	Take precautionary measures against static discharge.
P244	Keep reduction valves free from grease and oil.
P250	Do not subject to grinding/shock/friction.
P251	Pressurized container: Do not pierce or burn, even after use.
P260	Do not breathe dust/fume/gas/mist/vapours/spray.
P261	Avoid breathing dust/fume/gas/mist/vapours/spray.
P262	Do not get in eyes, on skin, or on clothing.
P263	Avoid contact during pregnancy/while nursing.
P264	Wash hands thoroughly after handling.
P265	Wash skin thouroughly after handling.
P270	Do not eat, drink or smoke when using this product.
P271	Use only outdoors or in a well-ventilated area.
P272	Contaminated work clothing should not be allowed out of the workplace.
P273	Avoid release to the environment.
P280	Wear protective gloves/protective clothing/eye protection/face protection.
P281	Use personal protective equipment as required.
P282	Wear cold insulating gloves/face shield/eye protection.
P283	Wear fire/flame resistant/retardant clothing.
P284	Wear respiratory protection.
P285	In case of inadequate ventilation wear respiratory protection.
P231 + P232	Handle under inert gas. Protect from moisture.
P235 + P410	Keep cool. Protect from sunlight.
Response
Code	Phrase
P301	IF SWALLOWED:
P304	IF INHALED:
P305	IF IN EYES:
P306	IF ON CLOTHING:
P307	IF exposed:
P308	IF exposed or concerned:
P309	IF exposed or if you feel unwell:
P310	Immediately call a POISON CENTER or doctor/physician.
P311	Call a POISON CENTER or doctor/physician.
P312	Call a POISON CENTER or doctor/physician if you feel unwell.
P313	Get medical advice/attention.
P314	Get medical advice/attention if you feel unwell.
P315	Get immediate medical advice/attention.
P320
P302 + P352	IF ON SKIN: wash with plenty of soap and water.
P321
P322
P330	Rinse mouth.
P331	Do NOT induce vomiting.
P332	IF SKIN irritation occurs:
P333	If skin irritation or rash occurs:
P334	Immerse in cool water/wrap n wet bandages.
P335	Brush off loose particles from skin.
P336	Thaw frosted parts with lukewarm water. Do not rub affected area.
P337	If eye irritation persists:
P338	Remove contact lenses, if present and easy to do. Continue rinsing.
P340	Remove victim to fresh air and keep at rest in a position comfortable for breathing.
P341	If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing.
P342	If experiencing respiratory symptoms:
P350	Gently wash with plenty of soap and water.
P351	Rinse cautiously with water for several minutes.
P352	Wash with plenty of soap and water.
P353	Rinse skin with water/shower.
P360	Rinse immediately contaminated clothing and skin with plenty of water before removing clothes.
P361	Remove/Take off immediately all contaminated clothing.
P362	Take off contaminated clothing and wash before reuse.
P363	Wash contaminated clothing before reuse.
P370	In case of fire:
P371	In case of major fire and large quantities:
P372	Explosion risk in case of fire.
P373	DO NOT fight fire when fire reaches explosives.
P374	Fight fire with normal precautions from a reasonable distance.
P376	Stop leak if safe to do so. Oxidising gases (section 2.4) 1
P377	Leaking gas fire: Do not extinguish, unless leak can be stopped safely.
P378
P380	Evacuate area.
P381	Eliminate all ignition sources if safe to do so.
P390	Absorb spillage to prevent material damage.
P391	Collect spillage. Hazardous to the aquatic environment
P301 + P310	IF SWALLOWED: Immediately call a POISON CENTER or doctor/physician.
P301 + P312	IF SWALLOWED: call a POISON CENTER or doctor/physician IF you feel unwell.
P301 + P330 + P331	IF SWALLOWED: Rinse mouth. Do NOT induce vomiting.
P302 + P334	IF ON SKIN: Immerse in cool water/wrap in wet bandages.
P302 + P350	IF ON SKIN: Gently wash with plenty of soap and water.
P303 + P361 + P353	IF ON SKIN (or hair): Remove/Take off Immediately all contaminated clothing. Rinse SKIN with water/shower.
P304 + P312	IF INHALED: Call a POISON CENTER or doctor/physician if you feel unwell.
P304 + P340	IF INHALED: Remove victim to fresh air and Keep at rest in a position comfortable for breathing.
P304 + P341	IF INHALED: If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing.
P305 + P351 + P338	IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.
P306 + P360	IF ON CLOTHING: Rinse Immediately contaminated CLOTHING and SKIN with plenty of water before removing clothes.
P307 + P311	IF exposed: call a POISON CENTER or doctor/physician.
P308 + P313	IF exposed or concerned: Get medical advice/attention.
P309 + P311	IF exposed or if you feel unwell: call a POISON CENTER or doctor/physician.
P332 + P313	IF SKIN irritation occurs: Get medical advice/attention.
P333 + P313	IF SKIN irritation or rash occurs: Get medical advice/attention.
P335 + P334	Brush off loose particles from skin. Immerse in cool water/wrap in wet bandages.
P337 + P313	IF eye irritation persists: Get medical advice/attention.
P342 + P311	IF experiencing respiratory symptoms: call a POISON CENTER or doctor/physician.
P370 + P376	In case of fire: Stop leak if safe to Do so.
P370 + P378	In case of fire:
P370 + P380	In case of fire: Evacuate area.
P370 + P380 + P375	In case of fire: Evacuate area. Fight fire remotely due to the risk of explosion.
P371 + P380 + P375	In case of major fire and large quantities: Evacuate area. Fight fire remotely due to the risk of explosion.
Storage
Code	Phrase
P401
P402	Store in a dry place.
P403	Store in a well-ventilated place.
P404	Store in a closed container.
P405	Store locked up.
P406	Store in corrosive resistant/ container with a resistant inner liner.
P407	Maintain air gap between stacks/pallets.
P410	Protect from sunlight.
P411
P412	Do not expose to temperatures exceeding 50 oC/ 122 oF.
P413
P420	Store away from other materials.
P422
P402 + P404	Store in a dry place. Store in a closed container.
P403 + P233	Store in a well-ventilated place. Keep container tightly closed.
P403 + P235	Store in a well-ventilated place. Keep cool.
P410 + P403	Protect from sunlight. Store in a well-ventilated place.
P410 + P412	Protect from sunlight. Do not expose to temperatures exceeding 50 oC/122oF.
P411 + P235	Keep cool.
Disposal
Code	Phrase
P501	Dispose of contents/container to ...
P502	Refer to manufacturer/supplier for information on recovery/recycling

Physical hazards
Code	Phrase
H200	Unstable explosive
H201	Explosive; mass explosion hazard
H202	Explosive; severe projection hazard
H203	Explosive; fire, blast or projection hazard
H204	Fire or projection hazard
H205	May mass explode in fire
H220	Extremely flammable gas
H221	Flammable gas
H222	Extremely flammable aerosol
H223	Flammable aerosol
H224	Extremely flammable liquid and vapour
H225	Highly flammable liquid and vapour
H226	Flammable liquid and vapour
H227	Combustible liquid
H228	Flammable solid
H229	Pressurized container: may burst if heated
H230	May react explosively even in the absence of air
H231	May react explosively even in the absence of air at elevated pressure and/or temperature
H240	Heating may cause an explosion
H241	Heating may cause a fire or explosion
H242	Heating may cause a fire
H250	Catches fire spontaneously if exposed to air
H251	Self-heating; may catch fire
H252	Self-heating in large quantities; may catch fire
H260	In contact with water releases flammable gases which may ignite spontaneously
H261	In contact with water releases flammable gas
H270	May cause or intensify fire; oxidizer
H271	May cause fire or explosion; strong oxidizer
H272	May intensify fire; oxidizer
H280	Contains gas under pressure; may explode if heated
H281	Contains refrigerated gas; may cause cryogenic burns or injury
H290	May be corrosive to metals
Health hazards
Code	Phrase
H300	Fatal if swallowed
H301	Toxic if swallowed
H302	Harmful if swallowed
H303	May be harmful if swallowed